Advertisement

DNP - Der Neurologe & Psychiater

, Volume 19, Issue 4, pp 24–28 | Cite as

Schlafstörungen

Wer profitiert von Melatonin?

  • Lukas Frase
  • Christoph Nissen
Fortbildung
  • 243 Downloads

Melatonin ist ein wichtiger Signalgeber für den zirkadianen Rhythmus — und ein entscheidender sowie oft unterschätzter Faktor für psychische und körperliche Gesundheit. Neben der Steuerung des Tag-Nacht-Rhythmus werden aktuell weitere Funktionen von Melatonin wie Wirkungen im Gastrointestinaltrakt, bei der Neuroprotektion nach Trauma oder in der Epilepsiebehandlung untersucht. Möglicherweise führen diese Untersuchungen zu neuen Therapieverfahren.

Literaturverzeichnis

  1. 1.
    Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of Melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80(10):2587.CrossRefGoogle Scholar
  2. 2.
    Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC et al. Extrapineal melatonin: Sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71(16):2997–3025.CrossRefPubMedGoogle Scholar
  3. 3.
    Pandi-Perumal SR, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe AD et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1):1–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Rivara S, Pala D, Bedini A, Spadoni G. Therapeutic uses of melatonin and melatonin derivatives: A patent review (2012 - 2014). Expert Opin Ther Pat 2015; 25(4):425–41.CrossRefGoogle Scholar
  5. 5.
    Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 2017; 34:10–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Riemann D, Baum E, Cohrs S, Crönlein T, Hajak G, Hertenstein E et al. S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 2017; 21(1):2–44.CrossRefGoogle Scholar
  7. 7.
    Herxheimer A. Jet lag. BMJ Clin Evid 2008; 2008.Google Scholar
  8. 8.
    Liira J, Verbeek JH, Costa G, Driscoll TR, Sallinen M, Isotalo LK et al. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev 2014; (8):CD009776.Google Scholar
  9. 9.
    Magee M, Marbas EM, Wright KP, Rajaratnam SMW, Broussard JL. Diagnosis, Cause, and Treatment Approaches for Delayed Sleep-Wake Phase Disorder. Sleep Med Clin 2016; 11(3):389–401.CrossRefPubMedGoogle Scholar
  10. 10.
    Johnsa JD, Neville MW. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder. Ann Pharmacother 2014; 48(12):1636–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Kunz D, Bes F. Melatonin Effects in a Patient with Severe REM Sleep Behavior Disorder: Case Report and Theoretical Considerations. Neuropsychobiology 2004; 36(4):211–4.CrossRefGoogle Scholar
  12. 12.
    Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med 2003; 4(4):281–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 2010; 19(4):591–6.CrossRefPubMedGoogle Scholar
  14. 14.
    McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: A critical review of evidence. Sleep Med 2015; 16(1):19–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6(1):85–95.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Schneider F, Härter M, Schorr S, editors. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression. 2. Auflage. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017. (Interdisziplinäre S3-Praxisleitlinien).Google Scholar
  17. 17.
    Guaiana G, Gupta S, Chiodo D, Davies SJC, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013; (12):CD008851.Google Scholar
  18. 18.
    Buoli M, Grassi S, Serati M, Altamura AC. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 2017; 18(13):1373–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Acufla-Castroviejo D, Escames G, Macks M, Hoyos AM, Carballo AM, Arauzo M et al. Minireview: Cell protective role of melatonin in the brain. J Pineal Res 1995; 19(2):57–63.CrossRefGoogle Scholar
  20. 20.
    Molina-Carballo A, Muñoz-Hoyos A, Sánchez-Forte M, Uberos-Fernández J, Moreno-Madrid F, Acuña-Castroviejo D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics 2007; 38(3):122–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Molina-Carballo A, Muñoz-Hoyos A, Reiter RJ, Sánchez-Forte M, Moreno-Madrid F, Rufo-Campos M et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years‘ experience. J Pineal Res} 1997; 23(2):97–105.CrossRefPubMedGoogle Scholar
  22. 22.
    Brzozowska I, Strzalka M, Drozdowicz D, Konturek SJ, Brzozowski T. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. Implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014; 20(30):4807–15.PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Psychiatrie und PsychotherapieUniversitätsklinikum Albert-Ludwigs-Universität FreiburgFreiburgDeutschland
  2. 2.Universitätsklinik für Psychiatrie und PsychotherapieBernSchweiz

Personalised recommendations